Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16531921 | 1.00 | TYK2 (0.46) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL17911316 | 0.93 | TYK2 (0.49) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL16531922 | 0.93 | TYK2 (0.49) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL16515658 | 0.87 | FYN (0.49) | AAK1 | |
| SCHEMBL16531912 | 0.87 | FYN (0.49) | AAK1 | |
| SCHEMBL17911317 | 0.84 | TYK2 (0.47) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL16531905 | 0.84 | TYK2 (0.47) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL17911311 | 0.82 | TYK2 (0.45) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL16531903 | 0.82 | TYK2 (0.45) | TYK2PDE4DCCNE1CDK2FLT3 | |
| SCHEMBL16515728 | 0.81 | HAVCR2 (0.36) | TYK2CCNE1CDK2FLT3AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | claimed |
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | AAK1, DAPK1, DAPK2 | TYK2 405/4885PDE4D 1890/4885CCNE1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.